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XMD8-92 是一种 BMK1 抑制剂，能够上调 p53 的表达。本研究中发现，































Cancer is the leading cause of death worldwide, and stomach cancer is one of the 
most frequently diagnosed ones. In less developed countries, stomach cancer is the 
third most frequently diagnosed cancer among men and the leading cause of cancer 
death. Owning to the suspected lymph nodes metastasis, sole surgical resection is 
usually not very effective. Therefore, chemotherapy has been widely used to treat 
advanced gastric cancer. However, the development of multidrug resistance (MDR) 
greatly limited the efficacy of chemotherapy.  
XMD8-92 has been widely used as a BMK1 inhibitor which is involved in p53 
up-regulation and chemotherapy anti-cancer capacity enhancement. We found that 
XMD8-92 is also a potent P-gp inhibitor which has the ability to reduce the 
expression of P-gp and reverse the multidrug resistance of MDR cells. Nanomedicine 
is another promising strategy to combat drug resistance. Compared to simple 
chemotherapeutic drug delivery nanomedicine, an improved MDR reversing method 
is to load the chemotherapeutic drug and chemosensitizing agents including 
transporter protein inhibitors or gene-silencing agents into one nanocarrier. In this 
context, we present a multifunctional thernostic DDS for cancer imaging and 
chemical therapy using poly(ethylene glycol)-blocked-poly(L-leucine) as the polymer 
backbone. The hydrophobic L-leucine core provides plenty of space for drugs loading, 
whereas the hydrophilic PEG shell is helpful for stabilization of the micelles and 
prolongs the blood circulation time[2-4][2-4]. As a commonly used cancer-targeting 
moiety, biotin was incorporated into the PEG-b-Leu backbone for tumor localization 
and effective cellular uptake. The chemotherapeutic drug Doxorubicin (DOX), 
chemosensitizing agents XMD8-92 and magnetic resonance imaging (MRI) agent 
superparamagnetic iron oxide (SPIO) were loaded into the Biotin-PEG-b-Leu DDS 
simultaneously (DXS@NPs) by simple one-step method and further delivered into 

















imaging that the accumulation of the DXS@NPs in tumor sites increased dramatically 
in 3 hours, and the DDS showed an improved anticancer drugs release under the 
tumor tissue’s acidic conditions. The DXS@NPs exhibited high performance to 
overcome cancer multidrug resistance, leading to excellent cytotoxicity on SCG 
7901/VCR cells.  In vitro and in vivo studies showed that DXS@NPs was much 
better than the free DOX administered simultaneously, in terms of both safety and 
antitumor efficacy. Except for up-regulation of p53, XMD8-92 plays an important role 
in P-gp down-regulation in vitro and in vivo. The nanocarriers we developed would 
be promising candidates with simultaneous delivery of DOX and XMD8-92 for 
treating MDR cancers. 
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